Milestone Pharmaceuticals Inc MIST

NAS: MIST | ISIN: CA59935V1076   30/04/2025
1,320 USD (+7,32%)
(+7,32%)   30/04/2025

13 november 2023 · Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates · Persbericht

11 november 2023 · Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023 · Persbericht

7 november 2023 · Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR · Persbericht

24 oktober 2023 · Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil · Persbericht

6 oktober 2023 · Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

27 september 2023 · Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023 · Persbericht

5 september 2023 · Milestone Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference · Persbericht

10 augustus 2023 · Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update · Persbericht

20 juni 2023 · Milestone Pharmaceuticals Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in The Lancet · Persbericht

1 juni 2023 · Milestone Pharmaceuticals to Present at the Jefferies Healthcare Conference · Persbericht

22 mei 2023 · Milestone Pharmaceuticals Announces Presentation of Data from Analysis of Etripamil Nasal Spray in Patients Experiencing Atrial Fibrillation with Rapid Ventricular Rate · Persbericht

11 mei 2023 · Milestone Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Corporate Update · Persbericht

8 mei 2023 · Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of Atrial Fibrillation with Rapid Ventricular Rate · Persbericht

12 april 2023 · Milestone Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference · Persbericht

29 maart 2023 · Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Corporate Update · Persbericht

28 maart 2023 · Milestone Pharmaceuticals Announces $125 Million Strategic Financing with RTW Investments to Support the Advancement of Etripamil for PSVT · Persbericht

6 maart 2023 · Milestone Pharmaceuticals Progresses Clinical and Regulatory Activities for Etripamil in Patients with Paroxysmal Supraventricular Tachycardia · Persbericht

28 februari 2023 · Milestone Pharmaceuticals to Present at Upcoming Investor Conferences · Persbericht

29 november 2022 · Milestone Pharmaceuticals to Host Virtual Commercial Deep-Dive Event on Etripamil for PSVT · Persbericht

22 november 2022 · Milestone Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare Conference · Persbericht

Mijn selecties